Sign in with Google
bullish
Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction
392 Views14 Sep 2022 11:38
SUMMARY
- Biocon Ltd (BIOS IN) divested 5.4% stake in Syngene International Ltd (SYNG IN) and raised INR12.2B. The proceed will be used to finance Biocon’s acquisition of biologics business of Viatris.
- Biocon is still working on the equity-debt split of Viatris deal, and a final decision on the same will be announced soon.
- The strategic deal with Viatris will transform Biocon Biologics into a leading vertically integrated global biologics company, with one of the broadest and deepest commercialized biosimilars portfolio in the industry.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Index Treatment of Sony (6758 JP)'s Spinoff of the Financial Services Business
- BYD (1211 HK/002594 CH) - Key Takeaways from AGM
- Xtalpi US$860m IPO Lockup Expiry - Last of the Lockup Release with Nearly All Shares in CCASS Now
- Austal (ASB AU): A Hanwha Bid Is Back In Play
- With Us (9696 JP): NSSK’s JPY3,237 Tender Offer
Top Unpaywalled Insights
More »- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
- [IO Technicals 2025/23] Bearish Momentum Persists
- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Biocon Ltd (BIOS IN): Stake Sale in Subsidiary Is a Step in Right Direction14 Sep 2022
x